Type I cytokine receptor TCCR
    1.
    发明申请
    Type I cytokine receptor TCCR 审中-公开
    I型细胞因子受体TCCR

    公开(公告)号:US20040234522A1

    公开(公告)日:2004-11-25

    申请号:US10663158

    申请日:2003-09-15

    CPC classification number: C07K14/715 A01K2217/075 A61K38/00 Y02A50/41

    Abstract: The present invention relates to methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in either the Th1 subtype or the Th2 subtype, based on the relative expression levels of the gene TCCR, and its agonists or antagonists. The present invention further relates to a method of diagnosing Th1- and Th2-mediated diseases.

    Abstract translation: 本发明涉及用于治疗和诊断免疫相关疾病的方法,包括由主要以Th1或Th2细胞响应于抗原刺激释放的细胞因子介导的那些。 本发明还涉及基于TCCR及其激动剂或拮抗剂的相对表达水平来偏置Th1亚型或Th2亚型中T细胞分化的方法。 本发明还涉及诊断Th1-和Th2介导的疾病的方法。

    Combination therapy
    2.
    发明申请
    Combination therapy 审中-公开
    联合治疗

    公开(公告)号:US20020197256A1

    公开(公告)日:2002-12-26

    申请号:US10099818

    申请日:2002-03-14

    Inventor: Iqbal Grewal

    Abstract: The invention provides for the treatment of diseases or disorders characterized by cells expressing the CD40 membrane glycoprotein. The invention provides methods for the treatment of various diseases or disorders characterized by cells expressing CD40 with a combination of an agent causes the depletion of cells expressing CD40 and a second agent which causes the depletion of cells expressing the CD20 membrane antigen. Pharmaceutical compositions and articles of manufacture such as kits comprising the agents and combinations thereof are also provided.

    Abstract translation: 本发明提供治疗以表达CD40膜糖蛋白的细胞为特征的疾病或病症。 本发明提供了治疗各种疾病或病症特征的方法,其特征在于表达CD40细胞的细胞与药物的组合导致表达CD40的细胞的消耗,以及引起表达CD20膜抗原的细胞消耗的第二药剂。 还提供药物组合物和制品,例如包含试剂及其组合的试剂盒。

Patent Agency Ranking